Document Detail


Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.
MedLine Citation:
PMID:  17163277     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of this study was to estimate the cost-effectiveness of schizophrenia relapse prevention in Spain using data from the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study. METHODS: Treatment of schizophrenia was modeled over 1 year using a retrospective deterministic model from the Spanish National Health System (NHS) perspective (year 2005). The primary outcome was the probability of relapse occurring within a 52-week period of treatment with daily doses of ziprasidone 40-160mg versus placebo. Data were obtained from a randomised, double-blind clinical trial (n = 218 patients). Antipsychotic cost, concomitant medications to treat adverse events (for example extrapyramidal symptoms) and medical costs associated with adverse events were derived from the clinical trial results and a Spanish health cost database. The average cost of a relapse admitted to hospital in Spain (3421 euro) was obtained from a retrospective study. RESULTS: The probability of psychosis relapse was 0.77 with placebo, and 0.43, 0.35, 0.36 and 0.38 with ziprasidone daily doses of 40, 80, 160mg and average dose, respectively (p < 0.01 vs placebo in all cases). The average annual incremental cost per relapse avoided was 186 euro for the average dose, ranging from a saving of 557 euro (80 mg/day) to an incremental cost of 1015 euro (160 mg/day), and was lower in all cases than the minimum cost of a relapse (2830 euro). CONCLUSIONS: According to this evaluation, psychosis relapse prevention with ziprasidone is cost effective compared with no treatment from the Spanish NHS perspective. Ziprasidone therapy avoids a considerable number of relapses at a reasonable cost, producing cost savings.
Authors:
Miguel Bernardo; Jose Ramón Azanza; Carlos Rubio-Terrés; Javier Rejas
Related Documents :
2127007 - Primary prevention of coronary heart disease in the federal republic of germany. analys...
11271867 - Chronic fatigue in general practice: economic evaluation of counselling versus cognitiv...
18360607 - Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cel...
9916907 - Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who develo...
1678937 - Psychotic depression: a review and clinical experience.
18297597 - Cognitive and functional outcomes of terror victims who suffered from traumatic brain i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical drug investigation     Volume:  26     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2006  
Date Detail:
Created Date:  2006-12-13     Completed Date:  2007-02-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  447-57     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Hospital Clinic i Provincial, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / administration & dosage,  economics,  therapeutic use
Chronic Disease
Cost-Benefit Analysis / methods
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Models, Econometric
Piperazines / administration & dosage,  economics,  therapeutic use*
Program Evaluation / methods
Recurrence
Reproducibility of Results
Schizophrenia / economics,  prevention & control*
Spain
Thiazoles / administration & dosage,  economics,  therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Piperazines; 0/Thiazoles; 146939-27-7/ziprasidone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between the frequency of blood pressure self-measurement and blood pressure reduction w...
Next Document:  Serum levels and possible haemodynamic effects following anorectal application of an ointment contai...